Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04150965 |
Title | Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | Multiple Myeloma Research Consortium |
Indications | |
Therapies | |
Age Groups: | senior | adult |
Covered Countries | USA |